Zacks Investment Research Upgrades BRENNTAG AG/ADR (OTCMKTS:BNTGY) to “Hold”

Share on StockTwits

BRENNTAG AG/ADR (OTCMKTS:BNTGY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Monday, Zacks.com reports.

According to Zacks, “Brenntag AG engages in the production and distribution of chemicals. It operates through the North America, Latin America, EMEA and Asia Pacific segments. Brenntag AG is headquartered in Mülheim an der Ruhr, Germany. “

Separately, ValuEngine downgraded Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 17th.

Shares of BNTGY opened at $10.32 on Monday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.21 and a current ratio of 1.76. BRENNTAG AG/ADR has a 1 year low of $8.20 and a 1 year high of $12.86. The firm’s 50 day moving average is $9.69. The stock has a market cap of $7.97 billion, a price-to-earnings ratio of 14.74, a P/E/G ratio of 1.63 and a beta of 1.27.

BRENNTAG AG/ADR (OTCMKTS:BNTGY) last announced its quarterly earnings data on Thursday, May 9th. The company reported $0.16 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.16. The business had revenue of $3.70 billion during the quarter. BRENNTAG AG/ADR had a net margin of 3.61% and a return on equity of 14.00%. As a group, equities research analysts expect that BRENNTAG AG/ADR will post 0.66 EPS for the current year.

About BRENNTAG AG/ADR

Brenntag AG, a chemical distribution company, purchases and supplies industrial and specialty chemicals in Europe, the Middle East, Africa, North America, Latin America, the Asia Pacific, and internationally. The company also provides value added services. It serves customers in various end-market industries, such as adhesives, paints, oil and gas, food, water treatment, personal care, and pharmaceuticals.

Read More: Bollinger Bands

Get a free copy of the Zacks research report on BRENNTAG AG/ADR (BNTGY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BRENNTAG AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRENNTAG AG/ADR and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Meridian Bioscience  Rating Lowered to Sell at ValuEngine
Meridian Bioscience Rating Lowered to Sell at ValuEngine
Unum Therapeutics  Price Target Lowered to $13.00 at Wedbush
Unum Therapeutics Price Target Lowered to $13.00 at Wedbush
Zendesk  Research Coverage Started at Compass Point
Zendesk Research Coverage Started at Compass Point
Afya  Coverage Initiated at Bank of America
Afya Coverage Initiated at Bank of America
Telefonica  Downgraded to “Neutral” at Bank of America
Telefonica Downgraded to “Neutral” at Bank of America


 
© 2006-2019 Zolmax.